1. Kruger S, Ilmer M, Kobold S, et al. Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res. 2019;38(1):268. DOI:10.1186/s13046-019-1266-0
2. Pauken KE, Dougan M, Rose NR, et al. Adverse Events Following Cancer Immunotherapy:Obstacles and Opportunities. Trends Immunol. 2019;40(6):511-23. DOI:10.1016/j.it.2019.04.002
3. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. DOI:10.1186/s40425-019-0805-8
4. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2-9.
5. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
6. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-91.
7. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48.
8. Puzanov I, Diab A, Abdallah K, et al;Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95.
9. Weber JS, Kähler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-7.
10. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors:a review. JAMA Oncol. 2016;2(10):1346-53.
11. Brahmer JR, Lacchetti C, Schneider BJ, et al. National Comprehensive Cancer Network. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;JCO2017776385.
12. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76-83.
13. Marin-Acevedo JA, Harris DM, Burton MC. Immunotherapyinduced colitis:an emerging problem for the hospitalist. J Hosp Med. 2018;13(6):413-8.
14. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review:colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406-17.
15. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis:imaging and clinicopathologic findings. Invest New Drugs. 2013;31(4):1071-7.
16. Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events:incidence of pancreatitis in patients treated with nivolumab plus ipilimumab. J Natl Cancer Inst. 2017;109(4).
17. Поддубская Е.В., Секачева М.И., Гурьянова А.А. Эндокринологические осложнения ингибиторов контрольных точек иммунитета: результаты одноцентрового исследования. Сеченовский вестник. 2019;10(4):4-11 [Poddubskaya EV, Sekacheva MI, Guryanova AA. Endocrine adverse events of immune checkpoint inhibitors:results of a single-center study. Sechenov Medical Journal. 2019;10(4):4-11 (in Russian)]. DOI:10.47093/22187332.2019.4.4-11
18. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82.
19. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9.
20. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092-9.
21. Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230-45.
22. Faje A. Immunotherapy and hypophysitis:clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82-92.
23. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):55-7.
24. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-17.
25. Денисова Е.С., Ардзинба М.С., Лактионов К.К., и др. Клинический случай иммуноопосредованного пневмонита после комбинированного лечения немелкоклеточного рака легкого. Медицинский совет. 2020;9:258-64 [Denisova ES, Ardzinba MS, Laktionov KK. A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer. Medicinskiy sovet. 2020;9:258-64 (in Russian)].
26. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 2017;69(4):687-99.
27. Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis:a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22(6):627-30.
28. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors:review of the literature. Eur J Cancer. 2017;73:1-8.
29. Wanchoo R, Karam S, Uppal NN, et al. Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors. Adverse renal effects of immune checkpoint inhibitors:a narrative review. Am J Nephrol. 2017;45(2):160-9.
30. Лактионов К.К., Саранцева К.А., Юдин Д.И., и др. Трехлетние результаты применения ниволумаба у больных с немелкоклеточным раком легкого в клинической практике национального медицинского исследовательского центра онкологии им. Н.Н. Блохина. Медицинский совет. 2019;19:16-21 [Laktionov KK, Sarantseva KA, Yudin DI, et al. Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Medicinskiy sovet. 2019;19:16-21 (in Russian)].
31. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55.
32. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
33. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415-26.
34. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33.
35. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK):a phase 3, open-label, multicentre randomized controlled trial. Lancet. 2017;389:255-65.
36. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13.
37. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67.
38. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283-94.
39. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-20.
40. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-26.
41. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATT RAC TION-2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461-71.
42. Oh DY, Cham J, Zhang L, et al. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res. 2017;77(6):1322-30. DOI:10.1158/0008-5472.CAN-16-2324
43. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9. DOI:10.1093/annonc/mdw640
44. Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715-20. DOI:10.1172/JCI96798
45. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39. DOI:10.1186/s40425-015-0081-1
46. Khan S, Khan SA, Luo X, et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer. 2019;120(1):63-8. DOI:10.1038/s41416-018-0155-1
47. Lee J, Phong B, Egloff AM, Kane LP. TIM polymorphisms – genetics and function. Genes Immun. 2011;12(8):595-604. DOI:10.1038/gene.2011.75
48. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-45. DOI:10.1038/ni1443
49. Heaney AP, Sumerel B, Rajalingam R, et al. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. J Clin Endocrinol Metab. 2015;100(11):4092-7. DOI:10.1210/jc.2015-2702
50. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage:Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018;67(8):1471-80. DOI:10.2337/dbi18-0002
51. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-7. DOI:10.1126/science.aan3706
52. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-79. DOI:10.1093/annonc/mdx108
53. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. ­Science. 2015;350(6264):1079-84. DOI:10.1126/science.aad1329
54. Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res. 2018;6(12):1445-52. DOI:10.1158/2326-6066
55. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069-86. DOI:10.1158/2159-8290.CD-18-0367
56. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. DOI:10.1056/NEJMoa1003466
57. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper. Ann Oncol. 2016;27(4):559-74. DOI:10.1093/annonc/mdv623
58. Grimm MO, Oppel-Heuchel H, Foller S. Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors:Immune-mediated side effects. Urologe A. 2018;57(5):543-51. DOI:10.1007/s00120-018-0635-1

________________________________________________

1. Kruger S, Ilmer M, Kobold S, et al. Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res. 2019;38(1):268. DOI:10.1186/s13046-019-1266-0
2. Pauken KE, Dougan M, Rose NR, et al. Adverse Events Following Cancer Immunotherapy:Obstacles and Opportunities. Trends Immunol. 2019;40(6):511-23. DOI:10.1016/j.it.2019.04.002
3. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. DOI:10.1186/s40425-019-0805-8
4. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2-9.
5. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
6. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-91.
7. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48.
8. Puzanov I, Diab A, Abdallah K, et al;Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95.
9. Weber JS, Kähler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-7.
10. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors:a review. JAMA Oncol. 2016;2(10):1346-53.
11. Brahmer JR, Lacchetti C, Schneider BJ, et al. National Comprehensive Cancer Network. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;JCO2017776385.
12. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76-83.
13. Marin-Acevedo JA, Harris DM, Burton MC. Immunotherapyinduced colitis:an emerging problem for the hospitalist. J Hosp Med. 2018;13(6):413-8.
14. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review:colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406-17.
15. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis:imaging and clinicopathologic findings. Invest New Drugs. 2013;31(4):1071-7.
16. Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events:incidence of pancreatitis in patients treated with nivolumab plus ipilimumab. J Natl Cancer Inst. 2017;109(4).
17. Poddubskaya EV, Sekacheva MI, Guryanova AA. Endocrine adverse events of immune checkpoint inhibitors:results of a single-center study. Sechenov Medical Journal. 2019;10(4):4-11 (in Russian) DOI:10.47093/22187332.2019.4.4-11
18. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82.
19. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9.
20. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092-9.
21. Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230-45.
22. Faje A. Immunotherapy and hypophysitis:clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82-92.
23. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):55-7.
24. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-17.
25. Denisova ES, Ardzinba MS, Laktionov KK. A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer. Medicinskiy sovet. 2020;9:258-64 (in Russian)
26. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 2017;69(4):687-99.
27. Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis:a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22(6):627-30.
28. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors:review of the literature. Eur J Cancer. 2017;73:1-8.
29. Wanchoo R, Karam S, Uppal NN, et al. Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors. Adverse renal effects of immune checkpoint inhibitors:a narrative review. Am J Nephrol. 2017;45(2):160-9.
30. Laktionov KK, Sarantseva KA, Yudin DI, et al. Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Medicinskiy sovet. 2019;19:16-21 (in Russian)
31. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55.
32. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
33. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415-26.
34. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33.
35. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK):a phase 3, open-label, multicentre randomized controlled trial. Lancet. 2017;389:255-65.
36. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13.
37. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67.
38. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283-94.
39. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-20.
40. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-26.
41. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATT RAC TION-2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461-71.
42. Oh DY, Cham J, Zhang L, et al. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res. 2017;77(6):1322-30. DOI:10.1158/0008-5472.CAN-16-2324
43. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9. DOI:10.1093/annonc/mdw640
44. Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715-20. DOI:10.1172/JCI96798
45. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39. DOI:10.1186/s40425-015-0081-1
46. Khan S, Khan SA, Luo X, et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer. 2019;120(1):63-8. DOI:10.1038/s41416-018-0155-1
47. Lee J, Phong B, Egloff AM, Kane LP. TIM polymorphisms – genetics and function. Genes Immun. 2011;12(8):595-604. DOI:10.1038/gene.2011.75
48. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-45. DOI:10.1038/ni1443
49. Heaney AP, Sumerel B, Rajalingam R, et al. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. J Clin Endocrinol Metab. 2015;100(11):4092-7. DOI:10.1210/jc.2015-2702
50. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage:Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018;67(8):1471-80. DOI:10.2337/dbi18-0002
51. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-7. DOI:10.1126/science.aan3706
52. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-79. DOI:10.1093/annonc/mdx108
53. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. ­Science. 2015;350(6264):1079-84. DOI:10.1126/science.aad1329
54. Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res. 2018;6(12):1445-52. DOI:10.1158/2326-6066
55. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069-86. DOI:10.1158/2159-8290.CD-18-0367
56. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. DOI:10.1056/NEJMoa1003466
57. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper. Ann Oncol. 2016;27(4):559-74. DOI:10.1093/annonc/mdv623
58. Grimm MO, Oppel-Heuchel H, Foller S. Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors:Immune-mediated side effects. Urologe A. 2018;57(5):543-51. DOI:10.1007/s00120-018-0635-1

М.А. Лядова*1, В.К. Лядов1–3

1 ГБУЗ «Городская клиническая онкологическая больница №1» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
3 Новокузнецкий государственный институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Новокузнецк, Россия
*dr.lyadova@gmail.com

________________________________________________

Marina A. Lyadova*1, Vladimir K. Lyadov1–3

1 City Clinical Cancer Hospital №1, Moscow, Russia;
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
3 Novokuznetsk State Institute of Postgraduate Medical Education – branch of the Russian Medical Academy of Continuous Professional Education, Novokuznetsk, Russia
*dr.lyadova@gmail.com